At the time of writing, Idexx Laboratories, Inc. [IDXX] stock is trading at $469.37, up 3.14%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IDXX shares have lost -1.12% over the last week, with a monthly amount drifted -2.97%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Idexx Laboratories, Inc. [NASDAQ: IDXX] stock has seen the most recent analyst activity on July 25, 2024, when BTIG Research initiated its Buy rating and assigned the stock a price target of $580. Previously, Piper Sandler downgraded its rating to Neutral on January 30, 2024, and kept the price target unchanged to $525. On December 07, 2023, Exane BNP Paribas initiated with a Outperform rating and assigned a price target of $602 on the stock. Cleveland Research upgraded its rating to a Buy. Atlantic Equities downgraded its rating to a Neutral but $610 remained the price target by the analyst firm on August 02, 2023. Stifel downgraded its rating to Hold for this stock on July 25, 2022, but kept the price target unchanged to $415. In a note dated July 21, 2022, Goldman upgraded an Buy rating on this stock and revised its target price from $530 to $435.
For the past year, the stock price of Idexx Laboratories, Inc. fluctuated between $372.50 and $583.39. Currently, Wall Street analysts expect the stock to reach $479.75 within the next 12 months. Idexx Laboratories, Inc. [NASDAQ: IDXX] shares were valued at $469.37 at the most recent close of the market. An investor can expect a potential return of 2.21% based on the average IDXX price forecast.
Analyzing the IDXX fundamentals
According to Idexx Laboratories, Inc. [NASDAQ:IDXX], the company’s sales were 3.72B for trailing twelve months, which represents an 7.10% jump. Gross Profit Margin for this corporation currently stands at 0.6% with Operating Profit Margin at 0.29%, Pretax Profit Margin comes in at 0.28%, and Net Profit Margin reading is 0.22%. To continue investigating profitability, this company’s Return on Assets is posted at 0.25, Equity is 0.57 and Total Capital is 0.47. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 459.83 points at the first support level, and at 450.29 for the second support level. However, for the 1st resistance point, the stock is sitting at 484.08, and for the 2nd resistance point, it is at 498.79.
Ratios To Look Out For
It is important to note that Idexx Laboratories, Inc. [NASDAQ:IDXX] has a current ratio of 1.51. Further, the Quick Ratio stands at 1.10, while the Cash Ratio is 0.36. Considering the valuation of this stock, the price to sales ratio is 10.41, the price to book ratio is 24.79 and price to earnings (TTM) ratio is 45.48.
Transactions by insiders
Recent insider trading involved Claflin Bruce L., Director, that happened on May 17 ’24 when 200.0 shares were sold. Executive Vice President, POLEWACZYK JAMES F completed a deal on Mar 06 ’24 to sell 8104.0 shares. Meanwhile, Director Vandebroek Sophie V. sold 1404.0 shares on Mar 05 ’24.
